Introduction
The pharmaceutical industry in India has witnessed remarkable growth over the past decade, positioning itself as a global leader in generic drug manufacturing. As of 2022, the Indian pharmaceutical market was valued at approximately USD 42 billion, with projections estimating growth to USD 65 billion by 2024. The demand for diabetes medications, particularly DPP-4 inhibitors like Alogliptin (Nesina), has significantly influenced the market landscape. With the rising prevalence of diabetes in India, which affects over 77 million people, the production and distribution of generic Alogliptin have become increasingly relevant.
Top 10 Alogliptin (Nesina) Generic Manufacturers in India
1. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical is one of India’s largest and most prominent pharmaceutical companies, known for its extensive range of generics, including Alogliptin. The company has a market share of around 7.4% in the Indian pharmaceutical sector and reported revenues exceeding USD 4.5 billion in 2021.
2. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a major player in India’s generic pharmaceutical market, with a strong focus on diabetes medications. The company holds a significant share of the DPP-4 inhibitor market and reported a revenue of approximately USD 2.6 billion in the 2022 fiscal year.
3. Lupin Pharmaceuticals
Lupin is recognized for its diverse portfolio, including various diabetes medications. With a production volume of over 1.5 billion units annually, the company is a key supplier of generic Alogliptin, contributing to its impressive revenue of USD 2.1 billion in FY 2022.
4. Aurobindo Pharma
Aurobindo Pharma has made significant inroads into the diabetes segment, particularly with its generic Alogliptin. The company reported a total revenue of USD 2.5 billion in FY 2022, with a focus on expanding its market presence in the U.S. and European markets.
5. Zydus Cadila
Zydus Cadila is a leading manufacturer known for its innovative approaches in drug development. The company has a substantial production capacity and reported revenues of USD 2.2 billion in FY 2021, focusing on expanding its portfolio in the diabetes care segment.
6. Torrent Pharmaceuticals
Torrent Pharmaceuticals has established itself as a formidable player in the generics market. In 2022, the company achieved a revenue of approximately USD 1.1 billion, with a robust pipeline that includes Alogliptin, catering to the growing diabetic population.
7. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is known for its strong commitment to research and development, particularly in chronic disease management. The company reported a revenue of USD 1.2 billion in FY 2022, with Alogliptin being a significant contributor to its diabetes segment.
8. Alkem Laboratories
Alkem Laboratories has been expanding its footprint in the diabetic treatment market. With a revenue of USD 1.0 billion in FY 2021, the company continues to enhance its generic offerings, including Alogliptin, to meet market demands.
9. Mylan (now part of Viatris)
Mylan, now operating under Viatris, has a significant presence in the Indian pharmaceutical market. The company’s extensive portfolio includes generic Alogliptin, contributing to its annual revenue of around USD 11.5 billion globally, with a notable share from the Indian market.
10. Hetero Drugs
Hetero Drugs is recognized for its focus on affordable medications, including generics for diabetes management. The company reported revenues of USD 1.0 billion in 2021, with a growing emphasis on expanding its Alogliptin production to cater to both domestic and international markets.
Insights
The market for generic Alogliptin (Nesina) in India is expected to continue its upward trajectory as the demand for diabetes treatments rises. According to market research, the global DPP-4 inhibitors market is projected to reach USD 9.5 billion by 2025, with India playing a crucial role due to its robust manufacturing capabilities. The increasing prevalence of diabetes, along with the shift towards affordable healthcare solutions, positions Indian manufacturers favorably in the global marketplace. Furthermore, the emergence of advanced technologies in drug formulation and production is likely to enhance the competitiveness of Indian companies, ensuring a steady supply of generic medications like Alogliptin to both domestic and international markets.
In summary, the landscape for Alogliptin production in India is evolving, with the top manufacturers emphasizing quality, affordability, and accessibility in their offerings.
Related Analysis: View Previous Industry Report
